Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06152575 · ClinicalTrials.gov registry record · Phase 3
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
A Phase 3 study of Multiple Myeloma, sponsored by Pfizer.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 492
- Enrollment target
- 20
- Study locations
NCT06152575: Recruiting Phase 3 study of Multiple Myeloma, sponsored by Pfizer.
NCT06152575 is a Phase 3 study of Multiple Myeloma that is actively recruiting participants, run by Pfizer. The registered enrollment target is 492 participants, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (10% lower). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06152575, a Phase 3 study of Multiple Myeloma, is actively recruiting participants, sponsored by Pfizer.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 492 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to learn about the study medicine called elranatamab.This study aims to compare elranatamab to other medicines for the treatment of MM (a type of cancer). This study is seeking participants who: * Are 18 years of age or older and have MM. * Have received treatments before for MM. * Have MM that has returned or not responded to their most recent treatment. Half of the participants will receive elranatamab. The other half of participants will receive a combination therapy selected by the study doctor. The selected combination therapy will include 2 to 3 different medicines commonly used to treat MM. Elranatamab will be given as a shot under the skin at the study clinic about once a week. This may change to a smaller number of shots later in the study. The medicines in the combination therapy will be taken by mouth (at home or at the study clinic) AND will be given either as: * a shot under the skin at the study clinic * through a needle in the vein at the study clinic The number of times these medicines will be taken depends on what combination therapy the study doctor selects. Participants may continue to receive elranatamab or a combination therapy until their MM is no longer responding. The study team will see how each participant is doing with the study treatment during regular visits at the study clinic. The study team will continue to follow-up with participants after study treatment with telephone contacts (or visits). The study will compare the experiences of people receiving elranatamab to those people receiving a combination therapy. This will help learn about the safety and how effective elranatamab is.
Primary Outcome
From date of randomization to date of progressive disease, discontinuation from study, death, or censoring, whichever occurs first
Conditions Studied
Interventions
- DRUG Dexamethasone
- DRUG Elranatamab
- DRUG Pomalidomide
- DRUG Bortezomib
- DRUG Elotuzumab
Study Locations (20)
California
- Beverly Hills Cancer Center - Beverly Hills
- Community Cancer Institute - Clovis
- Clinical Research Advisors (Encino Satellite Location) - Encino
- Hoag Health Center Irvine - Irvine
- Hoag Hospital Irvine - Irvine
- Clinical Research Advisors (Korea Town Satellite Location) - Los Angeles
- Clinical Research Advisors (West Hollywood Satellite Location) - Los Angeles
- Valkyrie Clinical Trials - Los Angeles
- Hoag Memorial Hospital Presbyterian - Newport Beach
- Mission Community Hospital (Satellite Site) - Panorama City
- University of California Davis (UC Davis) Comprehensive Cancer Center - Sacramento
- University of California - Sacramento
Colorado
- UCHealth Poudre Valley Hospital - Fort Collins
- UCHealth Harmony - Fort Collins
- UCHealth Greeley Hospital - Greeley
- UCHealth Longs Peak Hospital - Longmont
- UCHealth Longs Peak Medical Center - Longmont
- UCHealth - Medical Center of the Rockies - Loveland
Alabama
- Infirmary Cancer Care - Mobile
Arizona
- Western Regional Medical Center, Inc. dba. City of Hope Phoenix - Goodyear
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 492 participants |
| Start Date | 2024-02-08 |
| Est. Completion | 2027-12-30 |
| Phase | Phase 3 |
What NCT06152575 shows while recruiting
NCT06152575 is an interventional study that assigns participants to a tested intervention. The registered 492 participants enrollment target is mid-sized for trials with a published cap, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (10% lower).
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 5 interventions - of which Dexamethasone is the first listed.
NCT06152575 names 20 study sites across 4 states, led by California, Colorado, Alabama.
Frequently Asked Questions
What is clinical trial NCT06152575 about?
NCT06152575 is a clinical study titled "MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)". The purpose of this study is to learn about the study medicine called elranatamab.This study aims to compare elranatamab to other medicines for the treatment of MM (a type of cancer). This study is seeking participants who: * Are 18 years of age or older and have MM. * Have received treatments bef...
What is the current status of trial NCT06152575?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 492 participants. The study started on 2024-02-08. Estimated completion is 2027-12-30.
What conditions does trial NCT06152575 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT06152575?
The interventions under investigation include: Dexamethasone (DRUG), Elranatamab (DRUG), Pomalidomide (DRUG), Bortezomib (DRUG), Elotuzumab (DRUG).
Who is sponsoring clinical trial NCT06152575?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06152575 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06152575's enrollment target sits among peer trials
492 49th of 438 higher than 390 of 438 other Multiple Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Olanzapine 2.5 vs 5 mg in Quadruplet Nausea/Vomiting Prophylaxis Before High-Dose Melphalan
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
RECRUITING · Phase 3
-
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 3
-
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
RECRUITING · Phase 3
-
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 3
-
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05861973 · 492 participants · NA
SMARTer Weight Loss Management
- NCT05908331 · 492 participants · NA
MagicTouch for Treatment of In-Stent Restenosis in Coronary Artery Lesions
- NCT06953089 · 492 participants · Phase 2
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
- NCT03418961 · 491 participants · Phase 3
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI